The triple test as a screening technique for Down syndrome: Reliability and relevance

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 83-88

  Reynolds, Tim ^a  

^a QUEEN S HOSPITAL   (United Kingdom)

Author keywords

Antenatal; Down syndrome; Pregnancy; Screening test

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; INHIBIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOWN SYNDROME; FIRST TRIMESTER PREGNANCY; HUMAN; NON INVASIVE PROCEDURE; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT IDENTIFICATION; PREGNANT WOMAN; PRENATAL SCREENING; RELIABILITY; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

EID: 77955525583     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/ijwh.s8548     Document Type: Article

References (41)

1. Reynolds T, Penney M. The mathematical basis of multivariate risk analysis: with special reference to screening for Downs syndrome associated pregnancy. Ann Clin Biochem. 1990;27:452-458.
2. Spencer K. Accuracy of Down's syndrome risks produced in a prenatal screening program. Ann Clin Biochem. 1999;36:101-103.
3. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988;297:883-887.
4. Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal serum screening for Down's syndrome: the effect of routine ultrasound scan determination of gestational age and adjustment of maternal weight. Br J Obstet Gynecol. 1992;99:144-149.
5. Department of Health, UK National Screening Committee. NHS Fetal Anomaly Screening Programme (NHS FASP): Report 2006/2008. Available from: http://fetalanomaly.screening.nhs.uk/standardsandpolicies/getdata.php?id=11016. Accessed Jan 26, 2010.
6. Harrison G, Goldie D. Second-trimester Down's syndrome serum screening: double, triple or quadruple marker testing? Ann Clin Biochem. 2006;43:67-72.
7. Fuchs K, Peipert J. First Trimester Down Syndrome Screening: Public Health Implications. Semin Perinatol. 2005;29:267-271.
8. Perinatal Institute for Maternal and Child Health. 3 Stage contingency screening for Down's syndrome - Stafford pilot - Final report to the UK National Screening Committee. Available from: http://www.pi.nhs.uk/screening/downs/index_downscreeningreport.htm
9. Department of Health, UK National Screening Committee. National Down's Syndrome Screening Programme for England: Antenatal Screening - Working Standards for Down's Syndrome Screening 2007. Available from: http://fetalanomaly.screening.nhs.uk/standardsandpolicies/getdata.php?id=10849. Accessed Jan 26, 2010.
10. Department of Health, UK National Screening Committee. NHS Fetal Anomaly Screening Programme - Screening for Down's syndrome: UK NSC Policy recommendations 2007-2010: Model of Best Practice. Available from: http://fetalanomaly.screening.nhs.uk/standardsandpolicies/getdata.php?id=10848. Accessed Jan 26, 2010.
11. Department of Health, UK National Screening Committe. FASP Progress Update - Autumn 2009. Available from: http://fetalanomaly.screening.nhs.uk/standardsandpolicies/getdata.php?id=10848. Accessed Jan 26, 2010.
12. American College of Gynecologists. New Recommendations for Down Syndrome: Screening Should Be Offered to All Pregnant Women. Available from: http://www.acog.org/from_home/publications/press_releases/nr01-02-07-1.cfm. Accessed Jan 26, 2010.
13. Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol. 2009;200:459. e1-e9.
14. Genetics in Family Medicine: The Australian Handbook for General Practitioners. Available from: http://www.nhmrc.gov.au/_files_nhmrc/file/your_health/egenetics/practioners/gems/sections/03%20%20Testing%20and%20pregnancy%20WEB.pdf. Accessed Jan 26, 2010.
15. Society of Obstetricians and Gynecologists of Canada. Prenatal Screening for Fetal Aneuploidy. Available from: http://www.sogc.org/guidelines/documents/187E-CPG-February2007.pdf. Accessed Jan 27, 2010.
16. Reynolds T. Downs syndrome screening is unethical: Views of today's ethics committees. J Clin Path. 2003;56:268-270.
17. Bell M, Stoneman Z. Reactions to prenatal testing: reflection of religiosity and attitudes toward abortion and people with disabilities. Am J Ment Retard. 2000;105:1-13.
18. Julian C, Huard P, Gouvernet J, Mattei JF, Ayme S. Physicians' acceptability of termination of pregnancy after prenatal diagnosis in southern France. Prenat Diagn. 1989;9:77-89.
19. Bouchard L, Renaud M, Kremp O, Dallaire L. Selective abortion: a new moral order? Consensus and debate in the medical community. Int J Health Serv. 1995;25:65-84.
20. Stuck J, Faine J, Boldt A. The perceptions of Lutheran pastors toward prenatal genetic counseling and pastoral care. J Genet Couns. 2001;10:251-263.
21. Kuppermann M, Nease RF, Learman LA, Gates E, Blumberg B, Washington AE. Procedure-related miscarriages and Down syndrome-affected births: implications for prenatal testing based on women's preferences. Obstet Gynecol. 2000;96:511-516.
22. Moyer A, Brown B, Gates E, Daniels M, Brown HD, Kuppermann M. Decisions about prenatal testing for chromosomal disorders: perceptions of a diverse group of pregnant women. J Womens Health Gend Based Med. 1999;8:521-531.
23. Gudkov L, Tichtchenko P, Yudin B. Human genetic improvement: a comparison of Russian and British public perceptions. Bull Med Ethics. 1998;134:20-23.
24. Li Y, Shan Z, Teng W, et al. Maternal thyroid function abnormalities during pregnancy affect neuropsychological development of their children at 25-30 months. Clin Endocrinol. 2009; Oct 31 [Epub ahead of print].
25. Reynolds T. The Ethics of Antenatal Screening: Lessons from Canute. Clin Biochem Rev. 2009;30:187-196.
26. Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implications of fetal/maternal lymphocyte transfer. Lancet. 1969;1:1119-1122.
27. Simpson JL, Elias S. Fetal cells in maternal blood: prospects for non-invasive prenatal diagnosis. Ann N Y Acad Sci. 1994;731:1-8.
28. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-487.
29. Lo YMD, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med. 1998;339:1734-1738.
30. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. N Engl J Med. 2002;346:1502.
31. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RhD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008;336:816-818.
32. Lo YMD, Chiu RWK. Prenatal diagnosis: progress through plasma nucleic acids. Nat Rev Genet. 2007;8:71-77.
33. Lo YMD, Tsui NBY, Chiu RWK, et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med. 2007;13:218-223.
34. Tong YK, Jin S, Chiu RWK, et al. Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. Clin Chem. 2010;56:90-98.
35. Dawson A, Jones G, Matharu M, et al. Serum screening for Down's syndrome: a summary of one year's experience in South Wales. Br J Obstet Gynaecol. 1993;100:875-877.
36. Benn PA, Chapman AR. Practical and ethical considerations of noninvasive prenatal diagnosis. JAMA. 2009;301:2154-2156.
37. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenatal Diagn. 1996;16:143-152.
38. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening programme for trisomy 21 at 10-14 weeks using fetal NT, maternal serum free beta-hCG and PAPP-A. Ultrasound Obstet Gynecol. 1999;13:231-237.
39. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med. 1999;341:461-467.
40. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenatal Diagn. 2004;24:762-766.
41. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess. 2003;7:1-77.